Catalyst
Slingshot members are tracking this event:
MacroGenics (MGNX) Presents Data from Ongoing Phase 1 Study of Enoblituzumab in Several Tumor Types at 30th Annual SITC Meeting
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MGNX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 07, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Anti-b7-h3 Antibody, T-cell Immunomodulatory Role, Enoblituzumab, Refractory B7-h3-expressing Neoplasms, Neoplasms Expressing B7-h3
